Comparative Pharmacology
Head-to-head clinical analysis: PROCARDIA XL versus TARKA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCARDIA XL versus TARKA.
PROCARDIA XL vs TARKA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
Combination of trandolapril (angiotensin-converting enzyme inhibitor) and verapamil (calcium channel blocker). Trandolapril inhibits ACE, reducing angiotensin II production, leading to vasodilation and decreased aldosterone secretion. Verapamil blocks L-type calcium channels, causing coronary and peripheral vasodilation, and negative chronotropic/inotropic effects.
30-90 mg orally once daily, extended-release tablet.
Tarka (trandolapril/verapamil) is available as fixed-dose combinations: 1 mg/180 mg, 2 mg/180 mg, 2 mg/240 mg, 4 mg/240 mg. For hypertension, initial dose is 1 mg/180 mg orally once daily; titrate based on blood pressure response, maximum dose 8 mg/480 mg per day.
None Documented
None Documented
Terminal elimination half-life: 6-11 hours; clinical context: steady-state achieved after 2-3 days of once-daily dosing.
Trandolaprilat terminal t1/2 16–24 h (prolonged in renal impairment, e.g., CrCl <30 mL/min ~36 h); verapamil t1/2 6–12 h (active metabolite norverapamil t1/2 ~12 h)
Renal: 70-80% as metabolites, <1% unchanged; Fecal: 15-20% via bile.
Renal: trandolaprilat 33% (unchanged 13%), trandolapril 10%; fecal: 66% (trandolaprilat 21%, trandolapril 33%); verapamil: renal 70% (16% unchanged), fecal 16%
Category C
Category C
Calcium Channel Blocker
ACE Inhibitor + Calcium Channel Blocker